EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis

Fernando Gibran-Nunes iD, Henrique Pêcego iD, Juliana Santos, Yasmim Nunes iD, Bianca Freitas, Jacqueline Rena, Marcos Fogale, Aliana Ferreira, Maria Seiwald, Elisabetta Xue, Anita Cortez, Ana Fonseca und 4 weitere

Cancer · 01.08.2026 · 132 (15)

DOI: 10.1002/cncr.70543 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer, online erschienen am 22.07.2026. Verfasst von Fernando Gibran-Nunes und 15 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Therapies and Clinical Research Center, Hospital Sírio-Libanês, São Paulo, Brazil. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunoconjugates, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Loncastuximab tesirine, a CD19‐directed antibody–drug conjugate, is a therapy for relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), including after chimeric antigen receptor T‐cell therapy. This study summarized efficacy and safety across published cohorts.

Methods

The authors did a systematic review and meta‐analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus American Society of Hematology 2025 abstracts. They pooled single‐arm proportions using random‐effects proportional meta‐analyses with Freeman–Tukey transformation and reconstructed individual patient data from Kaplan–Meier curves for time‐to‐event pooling (protocol: PROSPERO CRD420251156779). Seven studies (596 patients) met inclusion criteria.

Results

Seven studies (596 patients) contributed to clinical outcomes across all analyses. Pooled overall response was 45.76% (95% CI, 28.75–63.28; I 2 = 94.3%), and the complete response was 18.83% (95% CI, 10.60–28.70, I 2 = 85.5%). Reconstructed data yielded a pooled median progression‐free survival of 5.18 months (95% CI, 3.97–6.15) and median overall survival was 9.01 months (95% CI, 7.60–10.73; four studies). Among responders, median duration of response was 10.22 months (95% CI, 6.37–not estimable). Grade ≥3 thrombocytopenia, neutropenia and anemia occurred in 23.71%, 18.80%, and 11.01% of patients, respectively, and treatment discontinuation due to adverse events occurred in 12.61% (95% CI, 5.85–21.18).

Conclusions

Loncastuximab tesirine shows clinically meaningful activity in heavily pretreated R/R DLBCL, including post–CAR T‐cell therapy settings, with frequent but manageable cytopenias. Pooled estimates showed substantial heterogeneity, driven mainly by real‐world cohorts, and should be interpreted with caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunoconjugatesImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseHumansTreatment OutcomeBenzodiazepines

Stichwörter der Autor:innen

CAR T‐cell therapydiffuse large B‐cell lymphomaloncastuximab tesirinemeta‐analysisrelapsed/refractory

Substanzen

Antibodies, Monoclonal, HumanizedImmunoconjugatesloncastuximab tesirineBenzodiazepines

Autor:innen und Institutionen

  • Advanced Therapies and Clinical Research Center, Hospital Sírio-Libanês, São Paulo, Brazil.
  • Department of Hematology, BMT and Cell Therapy, Hospital Sírio-Libanês, São Paulo, Brazil.
  • D'Or Institute for Research and Education, Rio de Janeiro, Brazil.
  • Afya Faculdade de Ciências Médicas de Palmas, Palmas, Brazil.
  • Faculdade Maurício de Nassau-Sergipe-Brazil, Aracaju, Brazil.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Fernando Gibran-Nunes, Henrique Pêcego, Yasmim Nunes

Förderung

  • NCI NIH HHS

Zitieren

APA

Gibran-Nunes, F., Pêcego, H., Santos, J., Nunes, Y., Freitas, B., Rena, J., Fogale, M., Ferreira, A., Seiwald, M., Xue, E., Cortez, A., Fonseca, A., Xavier, E., Serpa, M., Tucunduva, L., & Novis, Y. (2026). Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis. Cancer, 132(15). https://doi.org/10.1002/cncr.70543

Vancouver

Gibran-Nunes F, Pêcego H, Santos J, Nunes Y, Freitas B, Rena J, et al. Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis. Cancer. 2026;132(15). doi:10.1002/cncr.70543

BibTeX
@article{GibranNunes2026,
  author = {Gibran-Nunes, Fernando and Pêcego, Henrique and Santos, Juliana and Nunes, Yasmim and Freitas, Bianca and Rena, Jacqueline and Fogale, Marcos and Ferreira, Aliana and Seiwald, Maria and Xue, Elisabetta and Cortez, Anita and Fonseca, Ana and Xavier, Erick and Serpa, Mariana and Tucunduva, Luciana and Novis, Yana},
  title = {Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {15},
  doi = {10.1002/cncr.70543}
}
Kostenlos starten →